On January 6, 2021 Amgen (NASDAQ:AMGN) reported that it will present at the 39th Annual J.P. Morgan Healthcare Conference at 11:50 a.m. PT on Monday, Jan. 11, 2021 (Press release, Amgen, JAN 6, 2021, View Source [SID1234573588]). Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen’s website for at least 90 days following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 6, 2021 Alkermes plc (Nasdaq: ALKS) reported that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 39th Annual J.P. Morgan Healthcare Conference (Press release, Alkermes, JAN 6, 2021, View Source [SID1234573587]). The presentation will take place virtually on Wednesday, Jan. 13, 2021 at 10:00 a.m. EST (3:00 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 6, 2021 Nektar Therapeutics’ (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin,reported to present at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 11:50 a.m. Pacific Time (Press release, Nektar Therapeutics, JAN 6, 2021, View Source [SID1234573586]). The presentation and Q&A session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of the Nektar website: View Source This webcast will be available for replay until February 10, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 6, 2021 IMMUNOPRECISE ANTIBODIES LTD. ("IPA" or the "Company") (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, reported that its board of directors has approved the grant of 25,000 stock options (the "Options") under its stock option plan to acquire up to an aggregate of 25,000 common shares in the capital of IPA ("Common Shares") (Press release, ImmunoPrecise Antibodies, JAN 6, 2021, View Source [SID1234573584]). Each of the five non-executive directors of IPA has been granted 5,000 Options.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Each Option is exercisable for a period of five years from the date of grant at an exercise price of C$20.30 per Common Share. One quarter of the Options granted to each director will vest every three months from the date of grant.

On January 6, 2021 Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, reported that its Chairman, Chief Executive Officer and President, and Founder of Powering Precision Health (PPH), Kevin Hrusovsky, will be presenting on the Company’s growth and vision for the fifth consecutive year at the 39th Annual J.P. Morgan Healthcare Conference, taking place virtually (Press release, Quanterix, JAN 6, 2021, View Source [SID1234573583]). Hrusovsky’s session will take place on Wednesday, Jan. 13, 2021 at 3:40 p.m., EST (12:40 p.m., PST) and will be made available to attendees and public listeners here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Webcast Information

To access the live webcast of Quanterix’ presentation at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2021 at 3:40 p.m., EST, please visit: View Source;kiosk=true.

Replays of the webcasts will be available for a limited period following the conference.